Product Images Losartan Potassium

The text provides data from a study on the effectiveness of Atenolol and Losartan in reducing the risk of the primary endpoint, with an adjusted risk reduction of 13% and p-value of 0.021. The percentage of patients with the primary endpoint is not mentioned. The study was conducted over 66 study months.*

This appears to be a graph depicting the percentage of patients with either fatal or non-fatal stroke over a 66 month study period. It compares the effects of Atenolol and Losartan, two different medications. However, without further information it is difficult to interpret the specific results or draw conclusions.*

This text seems to describe a study or experiment that involved two drugs, Losartan and Atenolol, and their effectiveness in preventing stroke (fatal/non-fatal) in different demographics, such as age, gender, race, and medical history. The table also includes hazard ratios and event rates.*

The text appears to represent a graph or a chart showing a comparison between the effects of Losartan and Placebo in reducing the risk (of what is not specified). The chart displays a reduction of 16.1% in risk for the Losartan group compared to the Placebo group. The p-value is also mentioned as 0.022 which may signify the statistical significance of the results. The rest of the text seems to be the numbers and markings on the axes of the graph. Therefore, it can be inferred that the text may be from a medical or scientific study on the effectiveness of Losartan in reducing a particular risk.*

This is a prescription drug label for Losartan, a medication used for treating high blood pressure, kidney damage caused by diabetes, and other similar conditions. The label provides instructions for the storage of the drug and warns to keep it out of the reach of children. The drug is manufactured by West-Ward Pharmaceuticals Corp. and is available in tablets of 100mg strength. The label includes an NDC (National Drug Code) number and an expiration date.*